Nohla Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
Clinical Trials
5
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
NLA101 in Adults Receiving High Dose Chemotherapy for AML
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- Biological: NLA101Drug: Standard of Care (SOC) chemotherapy
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT03301597
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Leukemia of Ambiguous LineageAcute Myeloid Leukemia
- Interventions
- Biological: Ex-Vivo Expanded Cord Blood Progenitor Cell Infusion
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT01701323
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Donor Umbilical Cord Blood Transplant With or Without Ex-vivo Expanded Cord Blood Progenitor Cells in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, or Myelodysplastic Syndromes
- Conditions
- Acute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionChronic Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- Biological: Ex Vivo-Expanded Cord Blood Progenitor Cell InfusionRadiation: Total-Body IrradiationProcedure: Umbilical Cord Blood Transplantation
- First Posted Date
- 2012-09-21
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 163
- Registration Number
- NCT01690520
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
🇺🇸University of Colorado, Denver, Colorado, United States
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Acute Lymphoblastic Leukemia in RemissionChildhood Acute Myeloid Leukemia in Remission
- Interventions
- Procedure: umbilical cord blood transplantationBiological: ex vivo-expanded cord blood progenitor cell infusionRadiation: total-body irradiationOther: laboratory biomarker analysis
- First Posted Date
- 2010-08-05
- Last Posted Date
- 2019-03-05
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01175785
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Clofarabine, Cytarabine, and Filgrastim Followed by Infusion of Non-HLA Matched Ex Vivo Expanded Cord Blood Progenitors in Treating Patients With Acute Myeloid Leukemia
- Conditions
- Adult Acute Minimally Differentiated Myeloid Leukemia (M0)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid LeukemiaAdult Acute Megakaryoblastic Leukemia (M7)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloblastic Leukemia Without Maturation (M1)
- Interventions
- Biological: Ex-vivo expanded cord blood progenitor cell infusionOther: laboratory biomarker analysis
- First Posted Date
- 2009-12-14
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- Nohla Therapeutics, Inc.
- Target Recruit Count
- 29
- Registration Number
- NCT01031368
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States